Senior Research Associate II (SRA II), Cell Therapy Process Development

Alameda, CA
Technical Development /
Full-time /
On-site
GeneFab is looking to expand its Technical Development, we are looking to add an experienced and dedicated Senior Research Associate II, Cell Therapy Process Development. Our new SRA II will report directly to our Senior Manager, Technical Development and work out of our Alameda, CA HQ office.

Responsibilities:

    • Translate scientific understanding to development of cGMP cell therapy manufacturing unit operations (i.e. activation, expansion, gene editing (viral/non-viral), cryopreservation)  
    • Support designing and executing experimental studies for new manufacturing technologies  
    • Apply QbD principles to improve process performance and manufacturability  
    • Collect, interpret, and present technical experimentation results to project teams   
    • Author (e.g. study protocols, technical reports, ELNs) or support authoring (e.g. sampling plans, batch records, specifications) of key documentation to enable technology transfer   
    • Build and maintain strong and credible interactions with internal stakeholders   
    • Support delivery of phase-appropriate technology transfer strategies   
    • Serve as a technical resource and guide for evaluation of root cause analyses and continuous improvement initiatives  
    • Management of sample submissions, inventories, and raw materials testing/acquisition  
    • Flexible support of other C&GT laboratory operations as needed  

Qualifications:

    • BS/MS Degree in science/engineering with 4-6+ years of experience in laboratory setting (preferably cell therapy development/manufacturing)  
    • Experience with participating in lab focused process development and technology transfer activities   
    • Strong technical writing and communication skills to support both development and tech transfer applications   
$110,000 - $135,000 a year
About GeneFab 
GeneFab is a contract manufacturing and synthetic biology biofoundry focused on cell and gene therapies. GeneFab was formed in 2023 with a vision to combine industry leading expertise in synthetic biology with advanced cGMP capabilities in order to accelerate the development and commercialization of genetic medicines. GeneFab offers its customers an extensive technology platform and know-how that spans early stage product design, technical development, and cGMP compliant production. GeneFab's technology platform includes bioinformatic-guided discovery of cell type promoters, directed evolution of small molecule-regulated gene switches, and the engineering of highly sensitive kill switches for enhanced safety and control of cellular therapies.

We are committed to an inclusive and diverse GeneFab. We believe that different perspectives lead to better ideas, and better ideas allow us to better understand the needs and interests of our diverse GeneFab team. We welcome people of different backgrounds, experiences, abilities, and perspectives and are an equal opportunity employer.